Home / Health / CMS to Negotiate Weight-Loss Drug Prices
CMS to Negotiate Weight-Loss Drug Prices
24 Dec
Summary
- CMS will negotiate prices for GLP-1 weight-loss drugs.
- Pilot programs for Medicaid and Medicare begin in 2026 and 2027.
- Novo Nordisk and Eli Lilly drugs are included in the initiative.
The Centers for Medicare and Medicaid Services (CMS) announced plans to negotiate drug prices for widely used GLP-1 medications, signaling a significant move to enhance patient access to weight-loss treatments. This federal initiative is set to roll out through pilot programs, with Medicaid beneficiaries potentially benefiting starting in May 2026, followed by Medicare recipients in January 2027.
The negotiation process will encompass blockbuster drugs such as Novo Nordisk's Wegovy and Ozempic, alongside Eli Lilly's Zepbound and Mounjaro. These medications have gained considerable attention for their effectiveness in managing weight, making expanded coverage a key objective for healthcare policymakers.
This strategic decision by CMS represents a proactive step towards controlling healthcare costs and ensuring that essential treatments are more attainable for a larger segment of the population. The phased rollout allows for careful implementation and evaluation of the pilot programs.
